OraSure Technologies (OSUR) Set to Announce Earnings on Tuesday – MarketBeat

Sign up for MarketBeat All Access to gain access to MarketBeat’s full suite of research tools:
OraSure Technologies (NASDAQ:OSUR – Get Rating) will release its earnings data after the market closes on Tuesday, November 8th. Analysts expect OraSure Technologies to post earnings of ($0.06) per share for the quarter. OraSure Technologies has set its Q3 2022 guidance at EPS.
OraSure Technologies (NASDAQ:OSUR – Get Rating) last released its quarterly earnings results on Tuesday, August 9th. The medical instruments supplier reported ($0.03) EPS for the quarter, topping the consensus estimate of ($0.17) by $0.14. The company had revenue of $80.23 million during the quarter, compared to analyst estimates of $69.91 million. OraSure Technologies had a negative return on equity of 12.92% and a negative net margin of 24.18%. The firm’s revenue was up 39.3% on a year-over-year basis. During the same quarter last year, the business posted ($0.02) earnings per share. On average, analysts expect OraSure Technologies to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

OraSure Technologies Stock Down 0.2 %

OSUR traded down $0.01 on Wednesday, hitting $4.45. The company had a trading volume of 2,862 shares, compared to its average volume of 484,276. The company has a market cap of $323.16 million, a PE ratio of -4.91 and a beta of 0.01. OraSure Technologies has a 12-month low of $2.62 and a 12-month high of $11.45. The business’s fifty day simple moving average is $3.98 and its 200 day simple moving average is $4.03.

Analyst Upgrades and Downgrades

Separately, StockNews.com started coverage on OraSure Technologies in a research report on Wednesday, October 12th. They set a “sell” rating for the company.

Insider Buying and Selling at OraSure Technologies

In other OraSure Technologies news, Director Ronny B. Lancaster bought 50,000 shares of the company’s stock in a transaction on Friday, August 26th. The stock was acquired at an average price of $4.00 per share, for a total transaction of $200,000.00. Following the completion of the transaction, the director now directly owns 104,782 shares of the company’s stock, valued at $419,128. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. In other news, Director Ronny B. Lancaster purchased 50,000 shares of the stock in a transaction that occurred on Friday, August 26th. The stock was purchased at an average price of $4.00 per share, for a total transaction of $200,000.00. Following the completion of the acquisition, the director now owns 104,782 shares of the company’s stock, valued at $419,128. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Michael Celano purchased 12,000 shares of the stock in a transaction that occurred on Friday, August 12th. The stock was purchased at an average price of $4.49 per share, with a total value of $53,880.00. Following the acquisition, the director now directly owns 111,823 shares of the company’s stock, valued at approximately $502,085.27. The disclosure for this purchase can be found here. Insiders acquired 64,200 shares of company stock worth $263,538 over the last 90 days. Company insiders own 2.20% of the company’s stock.

Institutional Trading of OraSure Technologies

A number of large investors have recently modified their holdings of the company. FMR LLC raised its stake in OraSure Technologies by 249.6% in the second quarter. FMR LLC now owns 10,687 shares of the medical instruments supplier’s stock worth $29,000 after buying an additional 7,630 shares in the last quarter. 1832 Asset Management L.P. bought a new position in OraSure Technologies in the first quarter worth approximately $40,000. Eaton Vance Management raised its stake in OraSure Technologies by 117.4% in the first quarter. Eaton Vance Management now owns 17,036 shares of the medical instruments supplier’s stock worth $116,000 after buying an additional 9,200 shares in the last quarter. Hsbc Holdings PLC raised its stake in OraSure Technologies by 62.5% in the first quarter. Hsbc Holdings PLC now owns 21,009 shares of the medical instruments supplier’s stock worth $143,000 after buying an additional 8,082 shares in the last quarter. Finally, AQR Capital Management LLC bought a new position in OraSure Technologies in the second quarter worth approximately $163,000. Hedge funds and other institutional investors own 90.20% of the company’s stock.

About OraSure Technologies

(Get Rating)
OraSure Technologies, Inc, together with its subsidiaries, develops, manufactures, markets, and sells oral fluid diagnostic products and specimen collection devices in the United States, Europe, and internationally. It operates in two segments, Diagnostics and Molecular Solutions. The company's principal products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D.

See Also

• Get a free copy of the StockNews.com research report on OraSure Technologies (OSUR)
• 3 Reasons Snap Stock Could Snap Back
• Freshpet: A Fresh Time To Buy Into This Growth Story?
• Nomad Foods: A Defensive Stock on the Move
• The Market Is Suddenly All Ears on Warner Music Group
• Uber Stock Surge On The Back Of Profitabilty

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider OraSure Technologies, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and OraSure Technologies wasn’t on the list.
While OraSure Technologies currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Complete the form below to receive the latest headlines and analysts’ recommendations for your stocks with our free daily email newsletter:
Sign up for MarketBeat All Access to gain access to MarketBeat’s full suite of research tools:
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat’s trending stocks report.
Identify stocks that meet your criteria using seven unique stock screeners. See what’s happening in the market right now with MarketBeat’s real-time news feed. Export data to Excel for your own analysis.
MarketBeat All Access members have access to premium reports, best-in-class portfolio monitoring tools, and our latest stock picks.
Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.
Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies, and more.
As Featured By:
MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.
Twitter Facebook StockTwits Financial Juice YouTube

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided ‘as-is’ and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart’s disclaimer.

source